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Systolic blood pressure values might
further risk-stratify the adverse outcomes of
LVH in older patients with chronic kidney
disease
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Abstract
Background: LVH is highly prevalent in patients with CKD and is independently associated with subsequent
cardiovascular events.
We hypothesized that adding systolic blood pressure values to LVH might differentiate different subgroups of
patients at higher risk of cardiovascular events (CVE) and other adverse outcomes.
Methods: Retrospective cohort study of 243 patients older than 60 years with stages 1-5 pre-dialysis CKD. LVH was
assessed by electrocardiogram or echocardiogram.
Results: Cardiovascular events occurred in 7 patients (10.3%) among those with SBP <130 and no LVH, 8 patients
(10.5%) among those with SBP ≥130 and no LVH, 7 patients (21.2%) among those with SBP <130 and LVH and 25
patients (37.9%) among those with SBP ≥ 130 and LVH.
On multivariate analyses, comparing to SBP < 130 and no LVH, the HR for CVE in those with SBP ≥ 130 and LVH was
4 (1.75, 10.3), p = 0.0007; 2.13 (0.71, 6.32) p = 0.16 in those with SBP <130 and LVH and 1.20 (0.42, 3.51) p = 0.72 in
those with SBP ≥130 and no LVH.
No significant differences were noted in changes in renal function and mortality rates among the groups.
Conclusion: The combination of higher systolic blood pressure and LVH might identify older patients with CKD at
higher risk of cardiovascular outcomes.
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Background
Cardiovascular disease represents the main cause of
morbidity and mortality in patients with chronic kidney
disease (CKD).
Left ventricular hypertrophy (LVH) is a known mani-
festation of hypertensive target organ damage.
LVH is highly prevalent in patients with CKD and is
already present in the early stages of the disease. Its
prevalence increases with age, anemia, hypertension and
lower renal function [1, 2].
More advanced CKD at baseline may be associated with
larger longitudinal increases in left ventricular mass and
volume and greater deterioration in diastolic function [3].
On the other hand, more severe LVH is associated with
kidney function decline and progression to dialysis [4, 5].
In patients with CKD, LVH and other echocardio-
graphic parameters (including low EF) are independently
associated with subsequent cardiovascular events [6, 7].
Because of the above, treating hypertension is of para-
mount importance in CKD populations. At the same time,
the ideal blood pressure target in these patients is a sub-
ject of controversy. Retrospective studies in older patients
with CKD suggest mortality is increased for systolic blood
pressures (SBP) higher and lower than 130-139 mmHg
and DBP of 60-79 mmHg [8].
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The objective of this study was to assess the prognostic
value of combining LVH data with clinical data (SBP) as
markers of adverse outcomes in older patients with CKD.
Our hypothesis is that adding systolic blood pressure
values to LVH might help differentiate different sub-
groups of patients at higher risk of adverse outcomes.
Methods
After obtaining approval from the Rice Memorial Hospital
Institutional Review Board (Willmar MN), a retrospective
cohort study of 243 patients older than 60 years with
stages 1-5 pre-dialysis CKD was carried out. These pa-
tients were seen in a Nephrology clinic between January of
2013 and November of 2015.
Since prior studies in older patients with CKD suggest
that mortality is lower for a SBP around 130 mmHg, we
decided to use this value as reference [8].
CKD was defined as evidence of structural or functional
kidney abnormalities (abnormal urinalysis, imaging stud-
ies, or histology) that persisted for at least 3 months, with
or without a decreased glomerular filtration rate (GFR), as
defined by a GFR of less than 60 mL/min per 1.73 m2.
Exclusion criteria
Patients on renal replacement therapy, history of organ
transplant, patients younger than 60 years of age, pa-
tients with a clinical diagnosis of congestive heart failure
(CHF) at baseline, patients without LVH data.
Variables collected
Demographics, comorbidities, LVH assessment by elec-
trocardiogram (ECG) or echocardiogram and laboratory
data at baseline and during follow up.
Primary outcome: new cardiovascular events
Cardiovascular events (CVE) were defined as the compos-
ite of new episodes of acute coronary event, decompen-
sated heart failure and cerebrovascular accident (stroke,
transient ischemic attack) during the follow up period.
Secondary outcomes
End stage renal disease requiring dialysis; changes in GFR;
all-cause mortality. The cause of death was obtained from
the medical records or death certificates.
Estimation of blood pressure
Office systolic blood pressures (SBP) and diastolic blood
pressures (DBP) were measured with an automated de-
vice, using an adult cuff, with the patient in a seated pos-
ition. Pulse pressure was determined by subtracting the
DBP from the SBP. In the calculation of the mean blood
pressure, we used blood pressures collected during regular
visits to maintain consistency among all participants. A
median of 18 [10, 28] blood pressure readings were ob-
tained for each patient.
Definition of LVH
The patients included in the study had LVH evaluation
either by echocardiogram or electrocardiogram (ECG),
these reports were obtained from the medical chart. A
patient was deemed to have LVH if there was a report
(either by ECG or echocardiogram) diagnosing this con-
dition. LVH by echocardiogram is defined as a LVMI
(left ventricular mass index) ≥150 g/m2 [9].
LVH by electrocardiogram is defined by a Sokolow-Lyon
voltage amplitude of (SV1 + RV5 or RV6) ≥3.5 mV and/or
a Cornell voltage of (SV3 + RaVL) >2.8 mV.
Glomerular filtration rate (GFR)
GFR was estimated by the four-variable Modification of
Diet in Renal Disease formula (MDRD) [10].
Estimation of proteinuria
Random urine albumin (albumin-to-creatinine ratio,
expressed as mg/g) or total protein (protein-to-creatinine
ratio, expressed as mg/g) were obtained after reviewing
the medical chart.
Statistical analyses
Data are presented as mean and standard deviation if
normally distributed and median [25% and 75% percen-
tiles] or range if not. For parametric data, differences in
the mean were compared by ANOVA. For highly skewed
data, the Wilcoxon- Kruskal Wallis Test was used.
Differences in proportions were assessed by the Chi
square or Fisher’s exact test.
Survival curves were generated using the Kaplan-
Meier method. Cox proportional hazards models were
used to study associations and adjust for confounding
factors.
P values lower ≤0.05 were considered statistically signifi-
cant. All the analyses were performed using JMP statistical
software version 11.2.0 (SAS Campus Drive, Cary, NC).
Results
The baseline characteristics are depicted in Table 1.
Echocardiographic information was present in 160
patients. Electrocardiographic information was present
in 84 patients. Whenever the two were present, the
echocardiographic data was used for analyses.
Primary and secondary outcomes are reported in
Table 2. During the follow up period (median 2.5 years,
range 0.02-2.8) there were 47 cardiovascular events and
13 deaths. The incidence of cardiovascular events was
higher in those patients with LVH, especially in those
with a SBP ≥130 mmHg (Fig. 1).
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Table 1 Baseline characteristics
SBP < 130 and LVH
N = 33
SBP ≥130 and LVH
N = 66
SBP < 130 and no LVH
N = 68
SBP ≥130 and no LVH
N = 76
P value
Age, years, mean ± SD 76 ± 7.2 77.4 ± 8.9 72.8 ± 8.2 72.9 ± 8.2 0.002
Caucasian, % 31 (93.9) 65 (98.5) 67 (98.5) 71 (93.4) 0.38
Men, % 15 (45.4) 33 (50) 30 (44.1) 36 (47.4) 0.92
Obesity, % 23 (69.7) 31 (47) 38 (55.8) 38 (50) 0.15
Cancer, % 7 (21.2) 24 (36.4) 13 (19.2) 14 (18.4) 0.05
Ejection fraction, mean ± SD* 61 ± 7.2 60 ± 7.7 58 ± 7.8 61 ± 8.8 0.35
CAD, % 12 (36.3) 22 (33.3) 21 (30.9) 11 (14.5) 0.02
CVA, % 1 [3] 7 (10.6) 4 (5.9) 5 (6.6) 0.51
DM, % 18 (54.5) 32 (48.5) 32 (47) 38 (50) 0.91
HTN, % 29 (87.9) 62 (93.9) 64 (94.1) 71 (93.4) 0.71
A fib, % 8 (24.2) 11 (16.7) 9 (13.2) 10 (13.1) 0.49
Hyperlipidemia, % 24 (72.7) 41 (62.1) 55 (80.9) 56 (73.7) 0.11
Pulmonary disease, % 10 (30.3) 16 (24.2) 13 (19.1) 22 (28.9) 0.49
Chronic liver disease, % 1 [3] 4 [6] 5 (7.3) 2 (2.6) 0.52
ACEIs, % 17 (51.5) 32 (48.5) 29 (42.6) 39 (51.3) 0.73
ARBs, % 4 (12.1) 16 (24.2) 9 (13.2) 15 (19.7) 0.29
Calcium channel blockers, % 7 (21.2) 29 (43.9) 21 (30.9) 35 (46) 0.03
Beta blockers, % 21 (63.6) 46 (69.7) 38 (55.9) 35 (46) 0.03
Thiazide diuretics, % 13 (39.4) 29 (43.9) 29 (42.6) 34 (44.7) 0.96
Loop diuretics, % 11 (33.3) 21 (31.8) 19 (27.9) 24 (31.6) 0.93
K sparing diuretics, % 2 [6] 1 (1.52) 9 (13.2) 3 (3.95) 0.03
Clonidine, % 0 (0) 4 [6] 1 (1.5) 3 (3.95) 0.32
Vasodilators, % 2 [6] 17 (25.8) 7 (10.3) 5 (6.6) 0.004
SBP mmHg, mean ± SD 123.9 ± 4.13 140.5 ± 8 122 ± 5.3 139.3 ± 8.3 <0.0001
DBP mmHg, mean ± SD 69.7 ± 5.52 73.1 ± 7.32 70.9 ± 5.4 74.7 ± 6.6 0.0002
PTH pg/mL, median [IQR] 59 [35, 83] 56 [42, 82] 67 [36, 92] 65 [45, 96] 0.81
Hemoglobin g/dL, mean ± SD 13 ± 1.44 12.4 ± 1.89 12.7 ± 1.66 13 ± 1.84 0.13
Phosphorus mg/dL, mean ± SD 3.35 ± 0.43 4 ± 3.28 3.46 ± 0.66 3.43 ± 0.64 0.31
Bicarbonate mEq/L, mean ± SD 27.9 ± 2.96 27.2 ± 2.94 26.4 ± 3.32 26.9 ± 3.12 0.13
25-Vitamin D ng/mL, median [IQR] 31.8 [23, 43] 36.9 [26, 48.7] 38.7 [21.3, 48.7] 28.9 [19.8, 48.8] 0.54
Albumin g/dL, mean ± SD 4 ± 0.30 4 ± 0.31 4 ± 0.36 4.1 ± 0.32 0.36
Baseline GFR, mean ± SD 48.2 ± 18.1 45 ± 18.8 47.6 ± 2.3 53.3 ± 2.1 0.06
Proteinuria, mg/g, median [IQR] 100 [7, 214] 100 [46, 303] 74.4 [8.4, 104] 100 [16.7, 333] 0.01
IQR interquartile range, GFR glomerular filtration rate (cc/min/BSA), SBP systolic blood pressure, DBP diastolic blood pressure
*EF data was obtained in 146 patients
Table 2 Primary and secondary outcomes
SBP < 130 and LVH SBP ≥130 and LVH SBP < 130 and no LVH SBP ≥130 and no LVH P value
CVE, % 7 (21.2) 25 (37.9) 7 (10.3) 8 (10.5) <0.0001
Death, % 3 (9) 5 (7.58) 4 (5.9) 1 (1.32) 0.25
Changes in GFR during follow up (cc/min/BSA) -5.27 ± 9.48 -3.57 ± 12.1 -5 ± 15.4 -7.7 ± 13.2 0.31
ESRD, % 1 (3) 4 (6) 0 2 (2.63) 0.22
CVE cardiovascular events, BSA body surface area, ESRD end stage renal disease, GFR glomerular filtration rate
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Comparing to SBP < 130 and no LVH the unadjusted
HRs for CVE in those with SBP ≥ 130 and LVH was 4
(1.82, 10), p = 0.0003; 2.18 (0.74, 6.39), p = 0.14 in those
with SBP < 130 and LVH and 0.96 (0.34, 2.74) p = 0.94 in
those with SBP ≥ 130 and no LVH.
On multivariate analyses, after adjusting for confound-
ing factors, the association of LVH and SBP ≥130 with
CVE remained significant (Table 3).
No significant differences were noted in changes in
renal function and mortality rates among the groups, al-
though the number of events was fairly small to make
conclusions.
Discussion
In this study, we found the combination of achieved sys-
tolic blood pressure with the presence of LVH (either by
ECG or Echocardiogram) might stratify the risk of CVE
among older patients with CKD. Furthermore, there ap-
pears to be a graded risk, with worse outcomes in those
with a SBP ≥130 and LVH vs those with a lower SBP
and those without LVH.
Higher blood pressure, greater body mass index (BMI),
intravascular expansion, advancing age and male gender
are associated with an abnormal left ventricular geometry.
This cardiac hypertrophy ultimately leads to activation of
metabolic pathways that increase extracellular matrix
production leading to fibrosis. Fibrosis leads to reduced
contractility with myocardial wall stiffening, systolic and
diastolic dysfunction, cardiomyopathy, and congestive heart
failure. Changes in cardiac remodeling might be fluid, with
some patients reversing to normal geometry, especially with
optimal blood pressure control [11–14].
Other principles in the treatment of LVH in CKD pa-
tients include treatment of the anemia and secondary
hyperparathyroidism.
Unfortunately we did not have enough data to study
LV geometry and other echocardiographic parameters in
this study. Other studies have found that CV event-free
survival is significantly worse in the presence of concen-
tric LVH and eccentric LVH [15].
There is some evidence that a concentric pattern (vs
eccentric) portends a worse cardiovascular prognosis.
Fig. 1 Kaplan-Meier analyses of cardiovascular event-free survival according to LVH and SBP
Table 3 Multivariate model for cardiovascular events
HR (95%CI) P value
SBP <130 and LVH* 2.13 (0.71, 6.32) 0.16
SBP ≥130 and LVH* 4 (1.75, 10.3) 0.0007
SBP ≥130 and no LVH* 1.20 (0.42, 3.51) 0.72
*Using SBP < 130 and no LVH as comparison. Cox models were adjusted for
age, CAD, CVA, beta blocker use, vasodilator use, atrial fibrillation, obesity
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Others suggest that LVH by itself, regardless of the
geometry is associated with worse renal and cardiovas-
cular outcomes [16, 17].
The association of hypertension and adverse outcomes
has been well demonstrated. In this study we found no
difference in survival among the groups, although the
number of events is fairly small and definite conclusions
cannot be reached.
In the SPRINT trial, aiming for a SBP lower than
120 mm Hg, as compared with less than 140 mm Hg
was associated with lower rates of heart failure events,
cardiovascular deaths and total deaths [18].
On the other hand, retrospective studies have shown
increased mortality with lower blood pressures in the
elderly. Kovesdy et al found that patients with a SBP of
130 to 159 mm Hg combined with a DBP of 70 to 89 mm
Hg had the lowest adjusted mortality rates, comparing to
those with higher or lower BP readings [19].
In 21,000 patients older than 65 years with stage 3-5
CKD not yet on dialysis there was increased mortality
with a baseline SBP < 120 mmHg comparing to a SBP
between 131-140 mmHg. A SBP higher > 140 mmHg was
associated with increased mortality only in the younger
patients with CKD [20].
We believe the discrepancy about optimal blood pres-
sure targets in older patients might be related to the
presence of CHF, since hypotension in this setting has
been associated with reduced survival [21–24].
In this study, we excluded patients with a clinical diag-
nosis of CHF at baseline, so our findings cannot be ap-
plied to those patients with CKD and underlying CHF.
In a recent paper we have found that a low SBP (less
than 120 mmHg) was associated with worse survival in
patients with CKD, nonetheless that patient population
had more cardiovascular comorbidities at baseline (espe-
cially CHF). Based on our current findings we think
studies evaluating the optimal BP target in older patients
with CKD might need to differentiate among patients
with and without heart failure and LVH [25].
Although this was an observational study, the follow
up was extensive, given the unique geographical char-
acteristics of this population. Most patients receive
their care in one of two local clinics and are admitted
to one or two hospitals which share electronic medical
records. This allows for close follow up of outcomes of
interest.
Among the limitations of this study we cite the
retrospective design, small number of patients, lack of
significant number of minorities, inability to assess for
reversibility of LVH changes, use of ECG and echocar-
diographic criteria together, although in CKD patients
LVH on electrocardiogram is associated with a higher
increase in CV mortality than other traditional risk
factors [26].
Conclusion
The combination of higher systolic blood pressure and
LVH might identify older patients with CKD at higher
risk of cardiovascular outcomes. These results should be
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